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An email survey of midwives knowledge about CytoMegaloVirus (CMV) in 
Hannover and a skeletal framework for a proposed teaching program  
 
 
 
Abstract 
At present there is lack of information about CMV transmission given to midwives, general 
practitioners, neonatal pediatricians and nurses, with intrauterine transmission having 
profound consequences in terms of outcomes for the infected neonate. To identify one 
particular group of midwives knowledge about CMV, the research question surveyed 
midwives' knowledge of CMV. A quantitative electronic survey was the research method 
utilised in this study. To assess midwives knowledge about CMV, the first author emailed 
colleagues in Hannover and was in receipt of 40 completed questionnaires. Results 
showed that midwives have gaps in their knowledge about CMV and that an educational 
program is necessary to enlarge their understandings. Given the catastrophic 
consequences to the neonate of contracting congenital CMV, it is imperative that both 
health care professionals and women receive the educational message about prevention. 
In response an education program for lecturers has been proposed, which consists of 
eleven learning objectives.  
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An email survey of midwives knowledge about CytoMegaloVirus (CMV) in 
Hannover and a skeletal framework for a proposed teaching program  
 
Introduction 
The human CytoMegaloVirus (CMV) is a beta-herpesvirus and belongs to the family of 
Herpesviridae. It was first described by Ribbert in 1881, who mistakenly defined the large 
inclusion bearing cells as a kind of protozoa. In 1920, Goodpasture unearthed the viral 
etiology of these cells and used the term “cytomegalo”, comprised from “zytos” and 
“megalo”, the Greek words for “cell” and ”large” which refer to enlargement of the infected 
cells (Schleiss, 2010). In 1956, Weller, Smith and Rowe were able to isolate and grow the 
virus (Ho, 2008).  
 Humans are a desirable host for CMV. Transmission occurs via bodily fluids, e.g., 
urine, saliva, vaginal secretions, semen, breastmilk, blood transfusions and via organ 
transplants. In immunocompetent individuals, most CMV infections are mild and more 
often asymptomatic. In contrast, in immunocompromised individuals, e.g., those with HIV, 
organ transplants, premature infants and fetuses, the infection can cause encephalitis, 
retinitis, hepatitis, nephritis, splenomegaly and colitis. The latent period of CMV is 4-8 
weeks and is a time during which the virus becomes virulent. Infected individuals can 
continue to secret the virus for months and sometimes years post initial infection (Nyholm 
& Schleiss, 2010), with adults moreoften transmitting the virus sexually (Ludwig et al., 
2009). Like other members of the Herpes family, the virus establishes a life-long latency 
post primary infection and periodically reactivates.  
 
Awareness about CMV 
At present, there is lack of information about CMV transmission given to general 
practitioners, midwives, neonatal pediatricians and nurses. However, there have been 
some efforts to sensitize the public through self-help groups established by effected 
parents. For example, the “Stop CMV: the CMV Action Network” attempts to raise public 
awareness through campaigns and issue of brochures about CMV spread. Official health 
authorities, for example, the Centre for Disease Prevention (CDC) in USA have made 
efforts to inform the public and pregnant women about CMV.  
In recent years, several studies have been published about CMV (Bate et al., 
2010; Cannon, 2009; Colugnati et al., 2007; Cordier et al., 2010; Dollard et al., 2007; 
Jacobsen & Sifontis, 2010), which emphasizes interest in providing health promotion in 
relation to prevention. Despite efforts, a great deal of ignorance prevails. Korver et al. 
(2009) discovered several gaps in knowledge of Dutch doctors about infection modes and 
treatment possibilities. Cannon (2009) concluded that many obstetricians do not counsel 
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pregnant women about CMV prevention and as a consequence many pregnant women do 
not know about CMV and its implications for their child’s future. In a survey conducted by 
the CDC in the USA, CMV was the condition the general public knew least about (see 
Table 1). 
 
TABLE 1 HERE 
 
 In many countries great efforts have been made to inform pregnant women about 
the dangers of toxoplasmosis or listeriosis, with the number of CMV infections much 
higher. The Junger and Wilson (1968) criteria was revised in 2008 and has been adapted, 
updated and applied for screening pregnant women for a variety of infections (Andermann 
et al., 2008, app.5) (see Table 2). 
 
TABLE 2 HERE 
 
It is proposed that general newborn screening for CMV be considered for detecting 
asymptomatic infected children, so they can be pursued periodically for hearing and 
eyesight tests. Since hygienic precautions for seronegative women minimizes infection 
spread, doctors, midwives and medical staff should counsel pregnant women about CMV 
prevention, recognition and management. Most mothers are willing to practice preventive 
behaviour (Nigro & Adler, 2011, Cannon, 2009), with many who acquire CMV infection 
during pregnancy retrospectively wishing they had known about measures to minimize 
risk (Adler, 2011). 
The rationale underpinning this project is a recognized dearth of information and 
knowledge sharing amongst health care professionals who deal with childbearing women. 
This dearth of knowledge has profound consequences in terms of sequelae for an infected 
neonate (Korver et al., 2009; Cannon, 2009), with many pregnant women uninformed 
about CMV and its implications for their child’s health. To identify one particular group of 
midwives knowledge about CMV, the research question surveyed midwives' knowledge of 
CMV.  
 
Method 
A quantitative electronic survey was the research method utilised in this study. To date, no 
surveys in Germany have assessed midwives’ knowledge base in relation to CMV. Email 
seemed a quick, inexpensive and reasonable way to explore their comprehension. 
Consequently, a quantitative electronic survey was selected because it is an effective 
method by which to engage with a sizable population. Also, survey information provides a 
"snapshot" of the target population to establish a baseline from which the researcher can 
assess knowledge base.  
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Participants 
The study assessed a purposive and representative sample of midwives working in 
Hannover at the time of enquiry. The inclusion criteria included being registered and 
currently practicing as a midwife in Hannover at the time of data collection. To assess 
midwives knowledge about CMV, the first author emailed the 151 colleagues in her group 
email address book.  
 
Ethics 
Ethical approval was not required because the first author in capacity as a supervisor was 
addressing educational needs of midwives within her remit. Education in relation to CMV 
was of focal interest at the time of enquiry. Consent was implied in that participants 
elected to answer the questions placed. Confidentiality and anonymity was assured.   
 
Content validity assessment 
To assess content validity, two individuals with high credibility in terms of knowledge 
about midwifery were recruited. Their advice and guidance helped shape development of 
the questions to provide a meaningful evaluation of respondents’ knowledge about CMV. 
Alterations and additions were made in line with the feedback offered. 
 
Data collection 
Data was collected using a structured survey instrument consisting of four questions:   
(1) Since you have been working as a midwife, have you cared for women with CMV 
infections?   YES / NO 
(2) Do you feel well informed about CMV infection?   YES / NO 
(3) Do you know the most common sequelae of congenital CMV infection? YES/NO 
If so, please state. 
(4) Do you know measures that prevent spread of CMV infection in pregnant women?  
YES / NO 
If so, please state. 
In response to two rounds of emails to the 151 midwives, 40 (26.5%) completed and 
returned the questionnaire between the months of May and July in 2011.  
 
Data analysis 
The completed questionnaires were read in their entirety. Descriptive statistics were 
calculated in relation to respondents’ responses. To assimilate and provide 
comprehensive dissemination in relation to the four questions, data was inserted into a 
table. Relevant comments about proposed sequelae were transcribed into the table 
against anonymous and tagged participant numbers. 
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Validity 
To establish content validity, two expert researchers assessed the questions for whether 
or not they were in fact asking appropriate questions to identify midwives general 
knowledge about CMV. The questions were them piloted on two midwives for their 
interpretation of what was being asked. Minor alterations were made in line with the 
feedback offered. All data collected remained confidential and anonymity measures were 
imposed.  
 
Results 
Twelve out of forty (30%) of the participating midwives had previously provided care for 
women infected with CMV. Eight out of forty (20%) felt well informed about CMV infection. 
Eighteen out of forty (45%) stated to know about the most common sequelae from CMV, 
with only eleven out of eighteen (61%) mentioning “hearing impairment”. Thirteen out of 
forty (32.5%) affirmed to know measures that minimize risk of infection spread. Prevention 
measures cited by respondents included hygiene measures, staying away from small 
children, using condoms and being banned from work whilst actively infected with CMV. 
To view a summary of the results (see Table 3). 
 
TABLE 3 HERE 
Discussion 
Results of the questionnaire show that midwives have gaps in their knowledge about CMV 
and that an educational program is necessary to enlarge their understandings. 
Accordingly, it is proposed that an education program be instigated. To view a proposal of 
potential learning objectives that could be used to underpin a CMV educational program 
for midwives (see Table 4). 
TABLE 4 HERE 
 
What follows is examples of information that could be used to underpin such a program. 
 
TABLE 5 HERE 
(Learning Objective 1) General prevalence of CMV 
The CMV virus presents itself in every human population (Nassetta et al., 2009). The 
seroprevalence of the CMV virus varies with age, ethnicity and social status of groups 
within individual populations. Seroprevalence is the number of persons in a population 
who test positive for a specific disease based upon a blood serum specimen. Other rates 
differ, with prevalence higher in developing countries and within lower socioeconomic 
groups of developed countries (Staras et al., 2006). There are two infection peaks. The 
 7 
 
first is in the initial 2-3 years of life, and the second is in young adults who have recently 
become sexually active (Schottstedt et al., 2010). 
 
(Learning Objective 2) Prevalence of CMV in pregnancy 
The seroprevalence of CMV in pregnancy in Europe differs between 40-90% in women of 
childbearing age (Ludwig & Hengel, 2009). Kenneson and Cannon (2007) claim a 
seropositivity rate of 98%, whilst Foulon (2005) demonstrated a seroprevalence of 57% 
based upon (n = 7140) pregnant women. Predisposing factors to CMV spread include 
crowded living conditions and low household income (Bate et al., 2010). Primary infection in 
pregnancy occurs in approximately 0.15-2.0% of all pregnancies (Nigro & Adler, 2011). 
Women of higher socioeconomic groups have a prevalence of 2%, whilst women of lower 
socioeconomic groups have an incidence of 6% (Nassetta et al., 2009).   
 
(Learning Objective 3) Prevalence of congenital CMV infection 
CMV is the most common cause of maternal-fetal infection during pregnancy. Even 
though there is less risk of transmission in the first trimester, primary infection during this 
time is associated with the most severe fetal sequelae (Nigro & Adler, 2011). The risk of 
congenital infection is much higher for unborn infants whose mothers experience primary 
infection (32.3%), compared with those sero-positive prior to conception who have 
reactivation of the virus (1.4%) (Luck & Sharland, 2009). Dollard et al. (2007) reviewed 
data from 15 studies, accumulating a total number of (n = 117, 986) screened infants. The 
overall prevalence of CMV at birth was 0.7%, with 12.7% of these infants becoming 
symptomatic immediately post delivery, of which 40-58% developed permanent sequelae. 
13.5% of infected infants were asymptomatic at birth, but proceeded to develop 
permanent sequelae at later check-ups.  
 de Fries (2011) identified that a total of 6800 congenitally infected infants develop 
permanent sequelae in Europe annually. According to the CDC in the USA, the estimated 
numbers are totalled at 5500. The number of children infected with CMV in the USA who 
progress to develop medical conditions is higher than the number of children born with 
Downs Syndrome or Fetal Alcohol Syndrome in 2012 (CDC, 2012) (see Table 6). 
 
TABLE 6 HERE 
 
(Learning Objective 4) Sequelae of congenital CMV infection 
There are several clinical presentations of CMV in newborn infants. Cytomegalic Inclusion 
Disease (CID) is the most severe form of congenital infection. Almost all cases occur 
when the mother is primary infected. Bristow et al. (2011) identified 777 congenital CMV 
associated deaths in the USA over a period of 17 years. They calculated that out of 1000 
infected children, 5 will die (Dollard et al., 2007). CID is characterized by Intra Uterine 
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Growth Retardation (IUGR), hyperbilirubinemia, hepatosplenomegaly, seizures and 
thrombozytopenia leading to purpura. Some manifestations of CMV can affect the Central 
Nervous System (CNS) to cause microcephaly and mental retardation, which can cause 
learning disabilities, cerebral palsy, epilepsy, optic atrophy and hearing impairment 
(Schleiss, 2010). 10% of infants with symptomatic congenital CMV develop handicaps 
(Nassetta et al., 2009), which is a higher number than is quoted by Dollard et al. (2007)  
(see Table 7).    
TABLE 7 HERE 
 SNHL is the most common outcome from congenital CMV infection and is 
responsible for around 21% of all hearing loss at birth and 25% of deafness in children up 
to 4 years of age. Sensori Neural Hearing Loss (SNHL) occurs in 10-15% of infected 
infants, with 30-65% symptomatic at birth. Only half of these infants present with hearing 
loss at birth (Nigro & Adler, 2011), with late-onset SNHL manifesting by early school age. 
It is difficult to make a reliable predication of the percentage of (late-onset) sequelae 
following congenital CMV infection, as many infants are infected during the postnatal 
period. For example, through breastfeeding (Fowler, 2008).  
 
(Learning Objective 5) Prevention of CMV infection 
Development of a vaccine is a major public health priority (Revello et al., 2010, Nyholm & 
Schleiss, 2010, Ghandi et al., 2010), since no passive or active vaccine against CMV is 
currently available. Trials of a passive immunization that attempts to prevent cross 
placental fetal infection are in the very early stage of development (Nigro & Adler, 2011), 
with another 10 years anticipated before a tried and tested vaccine becomes available. 
Exposure to saliva and urine of small children is the main cause of primary CMV spread to 
pregnant women (Cannon & Davis, 2005). Infection rates are high for small children who 
attend daycare centers. Since pregnant women are key attendees at nurseries, it is 
important to provide them with information about CMV prevention and transmission. The 
European Congenital CMV Initiative (ECCI) and the CDC have developed 
recommendations about how to avoid infection spread (Hyde et al., 2010). Since only 1 in 
4 mothers actually become infected, this emphasizes that CMV is not that easily 
transmitted and that parental infection is in fact avoidable. Preventing transmission 
through behavioural change is the most effective and inexpensive way to decrease risk of 
CMV infection during pregnancy (Cordier et al., 2010).  
 
(Learning Objective 6) Maternal CMV screening  
Routine screening of pregnant women is a controversial topic. The gold standard of 
serologic diagnosis is maternal seroconversion and the detection of CMV-specific IgG with 
low and slowly increasing levels of CMV-specific IgM antibodies (Nigro & Adler, 2011). 
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Unfortunately, detection of antibodies does not predict primary infection reliably, since IgM 
antibodies not only occur in primary infections, but can also be present in reactivations or 
reinfections. A primary infection can only be diagnosed when maternal or fetal symptoms 
are present, as well as anti-CMV IgM antibodies and low-avidity anti-CMV IgG antibodies 
(Nigro & Adler, 2011). Another concern is that maternal immunity does not rule out a 
recurrent infection or an infection with a new CMV strain (Nyholm et al., 2010). Diagnosis 
of infection in utero cannot predict symptomatic disease, even if it is asumed that the fetus 
has active CMV virus. Also, there is no evidence-based treatment available. However, 
controversial voices claim that a general screening program for all pregnant women would 
reduce sequelae caused by the CMV virus (Colugnati et al., 2007; Harvey & Dennis, 
2008; Nigro & Adler, 2011). Teaching pregnant seronegative women prevention measures 
could seriously reduce infection spread. Cahill et al. (2009) propose that general 
screening of all pregnant women should be routine, instead of just high-risk women and 
those with abnormal ultrasound findings. Treating childbearing women with IgG and IgM 
antibodies in CMV intravenous immuneglobulin would achieve approximately 47% 
reduction in CMV and its associated sequelae (Cahill et al., 2009).  
 
(Learning Objective 7) Infant CMV screening  
There are several options about how to screen for CMV in newborns. These include, 
collecting saliva, urine and/or Polymerase Chain Reaction (PCR). PCR is a technique by 
which minute amounts of DNA can be replicated very rapidly and thereby amplified to 
such an extent that the DNA becomes easy to detect. Testing saliva or urine is more 
sensitive than a blood test, since the viral load is lower in blood. Real-time PCR assays of 
both liquid and dried saliva specimens show high sensitivity and specificity for detecting 
CMV infection, and therefore should be considered potential screening tools for CMV in 
newborns (Boppana et al., 2011). de Vries (2011) strongly recommends that post 
implementation, that a large scale study be conducted to test effectiveness of screening 
on outcome measures. The rationale is that early identification of congenital CMV would 
allow timely recognition of deafness, although screening infant hearing only discovers 
50% (up to 75% according to Nyholm & Schleiss, 2010) of all SNHL cases caused by 
CMV infection.  
(Learning Objective 8)Treatment of an infected mother 
There are two treatment options for a CMV infected mother. The first involves 
administration of CMV immunoglobulins or antiviral drugs (Valaciclovir) to reduce the rate 
of transmission and improve neonatal outcomes (Lazzarotta et al., 2011). There is 
however no evidence-base to confirm their efficiency (Mc Carthy et al., 2011). Treatment 
with Valaciclovir, which is Human CMV Human Globuline (HIG) has been recommended 
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by Nigro and Adler (2011). Benefits include: (1) there is no known toxicity, (2) it is easily 
available, and (3) cost is modest compared to what is spent on a child with CMV infection 
sequelae. Another study is presently examining the effectiveness of Valaciclovir and is 
projected to be complete in 2013 (Lazzarotto et al., 2011). 
 
(Learning Objective 9) Treatment of the CMV infected infant 
Currently there are four antiviral agents effective at eradicating CMV. These include:  
(1) Ganciclovir, (2) Valganciclovir, (3) Foscarnet, and (4) Cidofovir. At present none of 
these are approved for paediatric use and therefore experience of their outcome is limited. 
Foscarnet and Cidofovir are associated with severe side-effects, and so Ganciclovir and 
Valganciclovir have become the favoured drugs for treating children (Marshall & Koch, 
2009). Prevention of hearing deterioration is the main desired impact. One study of 
asymptomatic infected infants who received Ganciclovir has shown that none developed 
hearing loss, compared to 11.1% in the untreated group. In spite of this success treatment 
is not recommended (Ghandi et al., 2010), because toxicity of the drugs can cause 
neutropenia (most commonly), reproductive toxicity, teratogenicity and mutagenicity. As a 
consequence of high toxicity and the narrow therapeutic range of CMV antiviral 
medications, patients in receipt must be carefully monitored for potential adverse side 
effects (Jacobsen & Sifontis, 2010). 
Congenital CMV infection is still the most common cause of maternal-fetal 
infection. Efforts have been instigated to develop appropriate treatment for women with 
CMV and their infected children. These programs are still in the initial stages of 
development. Treating infected newborns is linked with potential risk of severe side-
effects. Consequently, it seems reasonable to propose that a general screening program 
for all women in the early antenatal period and ideally preconception is the best approach. 
Post booking screening, it is proposed that a second serological testing at 15-16 weeks of 
pregnancy takes place in seronegative women to detect seroconversion and possibly 
initiate treatment.  
  
Conclusion 
Given the catastrophic consequences to the neonate of contracting congenital CMV, it is 
imperative that both health care professionals and women receive the educational 
message about prevention (Osterholm et al.,1992). Education delivered from midwives 
about CMV should emphasize hygienic practices as a precaution for all women who are 
pregnant or planning to become pregnant. Education would be strengthened by using 
general public health messages about preventing infection spread; for example, teaching 
rigorous methods of hand hygiene, how to reduce sexual transmission and avoid spread 
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between children in day care facilities. Education as regard hygienic practices to reduce 
spread of CMV is relatively inexpensive and is capable of preventing disability. 
It is argued that an education program to extend midwives knowledge about CMV 
is required in Hannover. It is proposed that single study days are organised within the 
midwifery education institutions and a program rolled out that all midwives are required to 
attend. Post delivery an evaluation of effectiveness of the education program should be 
conducted. It is also recommended that the level and amount of CMV education in 
undergraduate midwifery curriculums is increased. Evidence supports that high quality 
training in prevention and management of CMV could profoundly improve mortality and 
morbidity statistics.  
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Table 1: Women’s awareness of conditions that  
affect children (CDC, 2012)  
_____________________________________________ 
Disease                                % of women aware 
_____________________________________________ 
Cytomegalvirus (CMV)     22% 
Parvovrus B19                 32% 
Congenital Toxoplasmosis     37% 
Congenital Rubella Syndrome (CRS)   53% 
Group B streptococcus (GBS)    59% 
Spina Bifida      76% 
Fetal Alcohol Syndrome (FAS)   83% 
Sudden Infant Death Syndrome (SIDS)   94% 
Down Syndrome      97% 
HIV/AIDS        98% 
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Table 2: Synthesis of emerging screening criteria proposed over the past 40 years  
(Andermann et al., 2008) 
____________________________________________________________________________ 
(1) The screening program should respond to a recognized need.  
(2) The objectives of screening should be defined at the outset. 
(3) There should be a defined target population. 
(4) There should be scientific evidence of screening program effectiveness. 
(5) The program should integrate education, testing, clinical services and program  
      management. 
(6) There should be quality assurance, with mechanisms to minimize potential risks of  
      screening. 
(7) The program should ensure informed choice, confidentiality and respect for autonomy. 
(8) The program should promote equity and access to screening for the entire target population. 
(9) Program evaluation should be planned from the outset. 
(10) The overall benefits of screening should outweigh the harm. 
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     Table 3: Summary of results of the Hannover participating midwives knowledge about CMV? 
 
Question 1   2   3     4     
n yes no yes no yes no proposed sequelae yes no prevention measures 
                      
1   1   1 1   SGA, immature infant, pneumonia   1   
2 1     1   1     1   
3   1 1   1   microcephaly, retardation   1   
4 1     1   1     1   
5   1   1 1   mental retardation 1   not stated 
6   1   1   1     1   
7   1   1   1     1   
8   1   1   1 mental impairment   1   
9   1   1   1     1   
10   1   1   1     1   
11   1 1   1   eye, ear and mental impairment 1     
12   1   1 1   eyes, cerebrum, ears 1   keep away from small children 
13   1   1 1   microcephaly  1   not stated 
14   1   1   1   1   hand washing after changing nappies and feeding 
15 1     1   1 mental impairment   1 handwashing 
16 1   1   1   microcephaly, retardation, hearing loss, eye impairment 1   
avoidance of contact, hygiene 
measures, ban from work 
17 1   1   1   deafness, meningitis 1   not stated 
18 1   1   1   mental and hearing impairment   1   
19 1     1   1     1   
20   1   1 1   mental impairment   1   
21 1     1   1 deafness   1   
22 1     1   1     1   
23   1 1   1   mental impairment,hardness of hearing 1   good hygiene 
24   1   1   1   1   not stated 
25   1   1 1   hearing disorder, mental and physical retardation 1   not stated 
26   1 1   1       1   
27 1     1   1 mental and hearing impairment, blindness   1   
28 1     1   1 prematurity, hepatosplenomegaly, seizures, SGA 1   dirt, smearinfection,kisses 
29   1   1   1     1   
30   1   1 1   impairment of the cardio-vascular system and  gastro-intestinal tract, microzephaly 1   not stated 
31   1   1   1     1   
32   1   1 1   mental impairment   1   
33   1   1 1       1   
34   1   1   1 neurological defects   1   
35   1   1   1     1   
36   1 1   1   mental and hearing impairment, severe multiple handicaps 1   
avoid smear infections, hand 
washing, ban of work 
37   1   1 1   SGA, prematurity, pneumonia   1   
38   1   1   1 prolonged icterus   1   
39   1   1   1     1   
40 1     1   1 fever,sucking weakness, flaccidity, Seizures, impairment of the CNS   1 facemask, condoms 
                      
total 12 28 8 32 18 22   13 27   
                      
percent 30,0 70,0 20,0 80,0 45,0 55,0   32,5 67,5   
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Table 4: Summary of proposed learning objectives for a CMV educational  
program for health care professionals that work with childbearing women 
____________________________________________________________ 
(1) Present a case study (see Table 5). 
(2) Provide a definition of (CMV) (see Introduction). 
(3) Discuss general prevalence of CMV (see Subsection 1). 
(4) Discuss prevalence of CMV in pregnancy (see Subsection 2). 
(5) Discuss prevalence of congenital CMV infection (see Subsection 3). 
(6) Discuss sequelae of congenital CMV infection (see Subsection 4). 
(7) Critically discuss how to prevent CMV infection (see Subsection 5). 
(8) Debate issues surrounding maternal CMV screening (see Subsection 6) 
(9) Debate issues surrounding infant CMV screening (see Subsection 7) 
(10) Discuss treatment of an infected mother (see Subsection 8). 
(11) Discuss treatment of an infected infant (see Subsection 9). 
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Table 5: Learning outcome one: a CMV case study  
____________________________________________________________________________ 
Paul was born in October 2010 by caesarean section. He is the second child in his family. His 
older brother Sebastian is 24 months older. Shortly after delivery Paul was referred to the 
intensive care unit with suspected group B streptococcal infection and treated with antibiotics. 
During the first three days of life Paul underwent numerous investigations. These included: 
blood taken from the umbilical cord and veins, urine specimens, ultrasound of the head and 
abdomen, tests for hearing and eyesight and a lumbar puncture. Symptoms of the infection 
rapidly reduced. Within days, Paul presented as a healthy newborn, with no obvious sign of 
pathology. Despite his healthy appearance, treatment was initiated. A central venous catheter 
was placed in Paul’s subclavian vein and he received intravenous treatment twice a day for the 
subsequent six weeks. During this time Paul was continuously monitored for side effects of the 
medication and for signs of disease using blood, ear and eye tests and ultra sound. His mother 
stayed with him in hospital for the duration of his treatment. His father took parental leave to 
care for the older son. This situation was highly stressful for the whole family. Paul’s mother 
Christiane had undergone a CMV screening early in her pregnancy. Findings from this 
investigation were seronegative. In efforts to reduce the risk for infection, Christiane was 
advised not to kiss her sons mouth. In the 31st week of Paul’s pregnancy, the second CMV 
screen was positive. Christiane was unable to recall any significant period of ill-health between 
the two tests. She did, however, note a mild cold during the end of her second trimester. It was 
assumed that CMV was most likely to have been contracted from the older son Sebastian. 
Christiane has been feeling considerable guilt about this, and regretted not taking the advice of 
her obstetrician seriously. Following the positive CMV result, various doctors were consulted. 
Christiane was provided with information regarding CMV hyperimmunglobuline treatment. As 
the unborn baby did not show signs of the disease, treatment was not recommended. Based 
upon this advice she opted against treatment. It can also be noted that this treatment would 
have been an off-label use (a drug prescribed to treat a condition for which it has not been 
approved by the responsible authority). The last few weeks of pregnancy were afflicted with 
great concern and worry about what could happen to her baby. Following Paul’s delivery and 
admission to intensive care, it became clear that Paul had been infected during the pregnancy. 
This was evidenced by a high virus load identified in blood and urine tests. No clinical signs of 
CMV were ever documented. 
 20 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 6: Children born with or developing long 
term medical conditions in the USA (CDC, 2012) 
______________________________________ 
Cytomegalovirus (CMV)                              5,500 
Fetal Alcohol Syndrome                              5,000 
Down Syndrome                                         4,000 
Spina Bifida / Anencephaly                         3,000 
Paediatric HIV / AIDS                                    200 
Invasive Homophillis / Influenza b (Hib)           60 
Congenital Rubella Syndrome (CRS)              10 
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Table 7: Estimates of sequelae among children with congenital CMV infection 
(out of 1,000)  (Dollard et al., 2007) 
__________________________________________________________ 
CMV infection   Symptomatic   Asymptomatic 
__________________________________________________________ 
Infected infant               127 (12.7%)   873 (87.3%) 
Deaths    5                                                  0 
Survivors                                     122                                              873 
With permanent sequelae           50-70 (40%-58%)                       118 (13.5%) 
________________________________________________________________ 
Conclusion                                  17–20% of the 1000 infected infants will have  
                                                    permanent sequelae; 1/3 from the symptomatic  
                                                    group and 2/3 from the asymptomatic group. 
